Israel Charo
Corporate Officer/Principal presso The University of California, San Francisco
Posizioni attive di Israel Charo
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| The University of California, San Francisco | Corporate Officer/Principal | 01/01/1991 | - |
Storia della carriera di Israel Charo
Precedenti posizioni note di Israel Charo
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| CHEMOCENTRYX, INC. | Direttore Tecnico/Scientifico/R&S | 01/09/2014 | - |
| Corporate Officer/Principal | 01/09/2014 | - | |
Bay City Capital LLC
 Bay City Capital LLC Investment ManagersFinance Bay City Capital LLC (Bay City Capital) is a venture capital firm founded in 1997 by Fred Craves, John Diekman, and Thomas Pritzker. The firm is headquartered in California, United States. | Investitore di Private Equity | 15/12/2010 | 15/12/2010 |
| Corporate Officer/Principal | 15/12/2010 | - |
Formazione di Israel Charo
| State University of New York at Downstate Medical Center | Doctorate Degree |
| Stony Brook University | Undergraduate Degree |
| University of California, Berkeley | Graduate Degree |
Statistiche
Distribuzione geografica
| Stati Uniti | 7 |
Posizioni
| Corporate Officer/Principal | 3 |
| Private Equity Investor | 1 |
| Chief Tech/Sci/R&D Officer | 1 |
Settori
| Consumer Services | 5 |
| Finance | 2 |
| Health Technology | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Aziende private | 2 |
|---|---|
Bay City Capital LLC
Bay City Capital LLC Investment ManagersFinance Bay City Capital LLC (Bay City Capital) is a venture capital firm founded in 1997 by Fred Craves, John Diekman, and Thomas Pritzker. The firm is headquartered in California, United States. | Finance |
ChemoCentryx, Inc.
 ChemoCentryx, Inc. Pharmaceuticals: MajorHealth Technology ChemoCentryx, Inc. is a biopharmaceutical company, which engages in the development and commercialization of medicines. It focuses on inflammatory disorders, autoimmune diseases, and cancer. Its drug candidates such as Avacopan and CCX140, selectively blocks a specific chemoattractant receptor, leaving the rest of the immune system intact. The company was founded by Thomas J. Schall in 1997 and is headquartered in San Carlos, CA. | Health Technology |
- Borsa valori
- Insiders
- Israel Charo
- Esperienza
